Zanganeh Maky's Form 4 filing
Summit Therapeutics Inc. (SMMT) · filed Mar 8, 2023
- Accession no.
- 0001599298-23-000028
- Filed
- Mar 8, 2023
- Trade date
- Mar 8, 2023
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market purchases total $24.7M. It was filed on the trade date.
This filing was later replaced by the amendment 0001387131-23-003381 (Mar 13, 2023). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Zanganeh MakyCIK 0001507650 | Director, Officer (Co-Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 8, 2023 | Common Stock | PPurchaseAcquired | +15,973,743 | $1.05 | +$16,772,430.15 | 23,395,269 | Direct | |
| Mar 8, 2023 | Common Stock | PPurchaseAcquired | +804,672 | $1.05 | +$844,905.6 | 1,178,529 | Indirect | |
| Mar 8, 2023 | Common Stock | PPurchaseAcquired | +6,748,629 | $1.05 | +$7,086,060.45 | 9,884,095 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.